Predicting and treating bone marrow fibrosis
The bone marrow is the soft tissue inside most bones where continuous production of blood cells takes place. In rare cases, these cells are replaced by scar tissue, leading to fibrosis and gradual inability to produce blood cells. At present, there are no biomarkers to predict this transition and no anti-fibrotic therapies. The EU-funded de-ALARMIN project is building upon the work of a previous ERC-funded project on a specific molecule of the innate immune system. This molecule can serve as a prognostic biomarker of bone marrow fibrosis, while its therapeutic targeting ameliorates symptoms and even reduces the associated blood cancer cell burden.
Fields of science
Funding SchemeERC-POC-LS - ERC Proof of Concept Lump Sum Pilot
3015 GD Rotterdam
See on map